Altay Therapeutics

Biopharmaceutical company developing small molecule transcription factor inhibitors for serious, underserved diseases, with a therapeutic area-agnostic drug discovery platform targeting allosteric sites on transcription factors.

VisitClaim or join

Founded: Not disclosed
Headquarters: Not disclosed
Company size: 1–10
Products tracked: 3

Products by Altay Therapeutics

3 products

DX5057First oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy (FSHD).0.00 reviewsDrug Discovery & Biotech

STAT3 InhibitorSmall molecule inhibitor that binds directly to the activated form of STAT3, demonstrating nanomolar potency, broad therapeutic relevance, and minimal off-target effects.0.00 reviewsDrug Discovery & Biotech

Undisclosed Oncology ProgramEarly candidates against an undisclosed transcription factor with relevance in sarcomas and prostate cancer.0.00 reviewsDrug Discovery & Biotech

Pricing for Altay Therapeutics

Contact sales

Contact Altay Therapeutics for current plans, volume pricing, and enterprise terms.

Trust profile

Security and compliance

No compliance claims have been published for this company.